BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12325066)

  • 21. Gliomatosis cerebri: treatment results with radiotherapy alone.
    Elshaikh MA; Stevens GH; Peereboom DM; Cohen BH; Prayson RA; Lee SY; Barnett GH; Suh JH
    Cancer; 2002 Nov; 95(9):2027-31. PubMed ID: 12404298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlative analysis of gene expression profile and prognosis in patients with gliomatosis cerebri.
    D'Urso OF; D'Urso PI; Marsigliante S; Storelli C; Luzi G; Gianfreda CD; Montinaro A; Distante A; Ciappetta P
    Cancer; 2009 Aug; 115(16):3749-57. PubMed ID: 19517475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular genetic alterations in gliomatosis cerebri: what can we learn about the origin and course of the disease?
    Mawrin C
    Acta Neuropathol; 2005 Dec; 110(6):527-36. PubMed ID: 16222524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma.
    Ushio Y; Tada K; Shiraishi S; Kamiryo T; Shinojima N; Kochi M; Saya H
    Front Biosci; 2003 May; 8():e281-8. PubMed ID: 12700122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.
    Broniscer A; Chamdine O; Hwang S; Lin T; Pounds S; Onar-Thomas A; Shurtleff S; Allen S; Gajjar A; Northcott P; Orr BA
    Acta Neuropathol; 2016 Feb; 131(2):299-307. PubMed ID: 26744350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.
    Kraus JA; Glesmann N; Beck M; Krex D; Klockgether T; Schackert G; Schlegel U
    J Neurooncol; 2000 Jun; 48(2):89-94. PubMed ID: 11083071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report].
    Inoue T; Kanamori M; Sonoda Y; Watanabe M; Sasajima T; Kamisato N; Kumabe T; Tominaga T
    No Shinkei Geka; 2008 Aug; 36(8):709-15. PubMed ID: 18700534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
    Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
    Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution of p53 alterations in a case of gliomatosis cerebri.
    Mawrin C; Lins H; Kirches E; Schildhaus HU; Scherlach C; Kanakis D; Dietzmann K
    Hum Pathol; 2003 Jan; 34(1):102-6. PubMed ID: 12605375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gliomatosis cerebri: report of 3 cases and review of recent literatures].
    Arai M; Kashihara K; Kaizaki Y; Taguchi M; Kitamura Y
    No To Shinkei; 2003 Oct; 55(10):890-7. PubMed ID: 14635518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.
    Glas M; Bähr O; Felsberg J; Rasch K; Wiewrodt D; Schabet M; Simon M; Urbach H; Steinbach JP; Rieger J; Fimmers R; Bamberg M; Nägele T; Reifenberger G; Weller M; Herrlinger U;
    Ann Neurol; 2011 Sep; 70(3):445-53. PubMed ID: 21710625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gliomatosis cerebri having a poor performance status without recurrence after radiotherapy: a single institutional experience.
    Jung TY; Yoon MS; Kim YH; Jung S; Kim IY; Jang WY; Moon KS; Lee KH; Kim SK
    Clin Neurol Neurosurg; 2015 Mar; 130():1-5. PubMed ID: 25569296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gliomatosis cerebri: review of 22 patients].
    Novillo López ME; Gómez-Ibáñez A; Rosenfeld M; Dalmau J
    Neurologia; 2010 Apr; 25(3):168-73. PubMed ID: 20492863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
    Ishii N; Maier D; Merlo A; Tada M; Sawamura Y; Diserens AC; Van Meir EG
    Brain Pathol; 1999 Jul; 9(3):469-79. PubMed ID: 10416987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations.
    Raffel C; Frederick L; O'Fallon JR; Atherton-Skaff P; Perry A; Jenkins RB; James CD
    Clin Cancer Res; 1999 Dec; 5(12):4085-90. PubMed ID: 10632344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients.
    Georgakis MK; Tsivgoulis G; Pourtsidis A; Petridou ET
    J Child Neurol; 2019 Jun; 34(7):394-401. PubMed ID: 30887873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
    Carroll KT; Hirshman B; Ali MA; Alattar AA; Brandel MG; Lochte B; Lanman T; Carter B; Chen CC
    World Neurosurg; 2017 Jul; 103():186-193. PubMed ID: 28366748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
    Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
    Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26-27, 2015, Paris, France.
    Greenfield JP; Castañeda Heredia A; George E; Kieran MW; Morales La Madrid A
    Pediatr Blood Cancer; 2016 Dec; 63(12):2072-2077. PubMed ID: 27466787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic pathways to glioblastoma: a population-based study.
    Ohgaki H; Dessen P; Jourde B; Horstmann S; Nishikawa T; Di Patre PL; Burkhard C; Schüler D; Probst-Hensch NM; Maiorka PC; Baeza N; Pisani P; Yonekawa Y; Yasargil MG; Lütolf UM; Kleihues P
    Cancer Res; 2004 Oct; 64(19):6892-9. PubMed ID: 15466178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.